Vaccine could delay bowel inflammation and colon cancer: research

Mar 24, 2010

An experimental vaccine against an abnormal protein found in some tumors has the potential to delay the onset of inflammatory bowel disease (IBD) and in turn prevent progression to colon cancer, according to researchers at the University of Pittsburgh School of Medicine. Their findings are reported this week in Cancer Prevention Research, a journal of the American Association for Cancer Research.

People with chronic inflammatory disorders such as IBD are at greater risk for developing cancer at the inflamed site, said senior author Olivera Finn, Ph.D., professor and chair, Department of Immunology, Pitt School of Medicine. In other cases, genes that develop cancerous changes can trigger inflammation. The vaccine made by her team is directed against an abnormal variant of a self-made cell protein called MUC1, which is altered and produced in excess in both IBD and colon cancer.

"Our experiments indicate that boosting the immune response against this protein early in the disease can delay IBD development, control inflammation and thereby reduce the risk of future cancers," Dr. Finn said. "These findings suggest also that the early stages of might be considered a premalignant condition."

The researchers tested transgenic mice that spontaneously develop IBD and then progress to colitis-associated colon cancer, producing the human version of MUC1 in both disease states. They found that animals that received the vaccine showed the first signs of IBD significantly later than those in two control groups that did not get the vaccine.

Microscopic evaluation of the colon tissue showed less inflammation in the vaccinated mice, and no indication of cancerous changes. Nearly half of the animals in each of the control groups had evidence of abnormal tissue, and two had colon cancer.

"The MUC1 vaccine seems to change the local environment from one that promotes cancer development to one that inhibits it," Dr. Finn said. "Certain that we usually see in the inflamed colon aren't present, and that could make the surroundings less friendly for potentially cancerous cells that also are directly targeted by the vaccine for destruction."

This study suggests that in the future the vaccine might be considered as part of the therapeutic regimen for IBD as well. The experimental has been studied in patients with colon and pancreatic cancer and currently is being tested as a prevention measure in patients who have a high risk for developing .

Explore further: New study identifies potential targets for personalized cancer vaccines

add to favorites email to friend print save as pdf

Related Stories

Vaccine to prevent colon cancer being tested in patients

Mar 19, 2009

Researchers at the University of Pittsburgh School of Medicine have begun testing a vaccine that might be able to prevent colon cancer in people at high risk for developing the disease. If shown to be effective, it might ...

Inflammation contributes to colon cancer

Jan 21, 2009

Researchers led by Drs. Lillian Maggio-Price and Brian Iritani at The University of Washington found that mice that lack the immune inhibitory molecule Smad3 are acutely sensitive to both bacterially-induced inflammation ...

Prostate cancer: Watchful wait or vaccinate?

Feb 01, 2008

Researchers at the University of Southern California have developed a prostate cancer vaccine that prevented the development of cancer in 90 percent of young mice genetically predestined to develop the disease. In the February ...

Recommended for you

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

10 hours ago

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, ...

Cancer exosome 'micro factories' aid in cancer progression

14 hours ago

Exosomes, tiny, virus-sized particles released by cancer cells, can bioengineer micro-RNA (miRNA) molecules resulting in tumor growth. They do so with the help of proteins, such as one named Dicer. New research from The University ...

User comments : 0